Association of Spexin Hormone Levels with Metabolic Disturbance in Women with Polycystic Ovarian Syndrome

Abstract

Background: Polycystic ovarian syndrome is affecting around 5–15% of females. Spexin hormone, identified as neuropeptide Q, has been newly recognized by bioinformatics methods.

Objective: To evaluate the relationship concerning levels of spexin hormone with   metabolic disruption in women with polycystic ovarian syndrome.

Patients and Methods: A case-control study carried out in the department of Obstetrics and Gynecology in Al-Imamain Al-Khademain medical city/Baghdad, Iraq, from Jan 1, 2022, to the end of Dec 31, 2022. The study sample comprises, 192 participants aged 18-45 years were joined and allocated into a case group (96 women with PCOS) and a control group (96 women without PCOS).

Results: Mean value of spexin hormone  was (2.7±0.3 ng/mL) in the PCOS group, while it was (3.5±0.7 ng/mL) in the control group; fasting blood sugar shows significant association with a negative, weak correlation with Spexin in patients (P-value= 0.005), Insulin shows significant association with inverse correlation with Spexin in patients (P-value= 0.04), Homeostasis model valuation of insulin resistance (HOMA-IR) shows significant association with inverse correlation with Spexin in patients (P-value= 0.003). Spexin had a significant inverse correlation with LH, SHBG, testosterone, FAI, and Dehydroepiandrosterone.

Conclusion: Serum level of spexin hormone was meaningfully decreased in patients with PCOS than that in healthy women.